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Resveratrol has been widely investigated for its potential health properties, although little is known about its metabolism in vivo. Here we inves-
tigated the distribution of metabolic products of [3H]trans-resveratrol, following gastric administration. At 2 h, plasma concentrations reached
1·7 % of the administered dose, whilst liver and kidney concentrations achieved 1·0 and 0·6 %, respectively. Concentrations detected at 18 h
were lower, being only 0·5 % in plasma and a total of 0·35 % in tissues. Furthermore, whilst kidney and liver concentrations fell to 10 and
25 %, respectively, of concentrations at 2 h, the brain retained 43 % of that measured at 2 h. Resveratrol-glucuronide was identified as the
major metabolite, reaching 7mM in plasma at 2 h. However, at 18 h the main form identified in liver, heart, lung and brain was native resveratrol
aglycone, indicating that it is the main form retained in the tissues. No phenolic degradation products were detected in urine or tissues, indicating
that, unlike flavonoids, resveratrol does not appear to serve as a substrate for colonic microflora. The present study provides additional information
about the nature of resveratrol metabolites and which forms might be responsible for its in vivo biological effects.
Resveratrol: Metabolism: Polyphenol: Radioactive: Distribution
Resveratrol (3,5,40-trihydroxy-trans-stilbene), a natural poly-
phenol identified as a biologically active compound in red
wine (Siemann & Creasy, 1992), has been the focus of various
in vivo and in vitro studies aimed at investigating its effect on
multiple pathophysiological processes and conditions. It has
been reported to possess anti-inflammatory (Kimura et al.
1985), vasorelaxing (Jager & Nguyen-Duong, 1999) and
anti-tumour (Jang et al. 1997; Lu & Serrero, 1999) properties,
and it has been demonstrated to inhibit platelet aggregation
(Kimura et al. 1985) and lipid peroxidation (Fauconneau et al.
1997) ex vivo. These bioactivities of resveratrol have been
proposed to be causally linked to the lower prevalence of
CHD that is epidemiologically associated with a moderate
consumption of red wine (Soleas et al. 1997).
Despite the number of studies published on the biological
activity of resveratrol, our knowledge regarding absorption,
metabolism and, especially, tissue distribution of resveratrol
is limited. However, it has previously been established that
O-glucuronidation, occurring either in the small intestine
(Spencer et al. 1999) or in the liver (Scheline, 1991), rep-
resents a major metabolic pathway for various phenolic phyto-
chemicals, including resveratrol and the more complex
flavonoids. In this context, Soleas et al. (2001) have demon-
strated that following intra-gastric administration of
[H3]trans-resveratrol, the overall levels of radiolabelled com-
pounds in serum declined far more slowly than those of the
radiolablled test compound, suggesting the presence of
metabolism-derived resveratrol derivatives. Indeed, resvera-
trol-3-O-glucuronide was later identified as the most abundant
metabolite of resveratrol in the rat (Marier et al. 2002; Yu
et al. 2002) and in human plasma (Goldberg et al. 2003;
Wang et al. 2004) following the ingestion of chemically
pure resveratrol. In addition, previous studies (Vitrac et al.
2003) have also demonstrated the presence of glucuronidated
resveratrol derivatives in certain tissues of rat. However, little
is known about the dynamics of resveratrol metabolism, and
effects of time on the tissue distribution and the excretion of
resveratrol and its main structurally related metabolites.
Other plant-derived phenolic compounds, including various
flavonoids, have also been shown to undergo biotransform-
ation by the colonic microflora (Rechner et al. 2002), thus
yielding small, structurally distinct cleavage products that
are often hydroxylated derivatives of simple phenolic acids
or g-valerolactones. In this context it is interesting to note
that the resveratrol products that arise from colonic fermenta-
tion processes are yet to be identified.
The present study was aimed at investigating the time-
dependent appearance and disappearance of [3H]resveratrol
in circulation, and to study the distribution of resveratrol
and its main metabolites among various organs including
liver, kidney, brain, lungs, heart and spleen. In addition, the
radiolabelled compounds present in plasma, urine and stool
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were analysed by HPLC using flow-through radioactivity and
photodiode array detectors in order to distinguish between
native resveratrol and its metabolites, and, if possible, to
identify main resveratrol-derived compounds that either arise
from cellular or colonic biotransformations.
Materials and methods
Chemicals
[3H]trans-Resveratrol was purchased from Moravek Bio-
chemicals Inc. (Brea, CA, USA). Radiochemical purity was
established by the supplier to be 99·8 % using HPLC analysis.
Specific activity determined by MS was 133·2 GBq/mmol.
Unlabelled resveratrol as well as all other chemicals were
obtained from Sigma Chemical Co. (St Louis, MO, USA).
Animals and sample preparation
The study used 250 g male Sprague-Dawley rats obtained from
the Comparative Biology Unit at the Royal Free & University
College Medical School, and maintained on standard rat chow
(Diet RM1, SDS Ltd, Witham, UK). Two groups of animals
(n 6) were administered via gastric gavage, 50 mg/kg body
weight resveratrol mixed with 1·85 MBq [3H]resveratrol and
dissolved in 1 ml 50 % aqueous ethanol. Three additional
rats were used as controls and received only 50 % aqueous
ethanol. All animals were fasted for 4 h prior to resveratrol
administration. All the procedures were conducted according
to the guidelines set out in the UK Animals (Scientific Pro-
cedures) Act 1986.
At 2 or 18 h post-gavage, animals were anaesthetized by
intraperitoneal injection of pentobarbitone sodium (90 mg/
kg; Sagital; Rhone-Merieux, Harlow, UK). Then, 0·3 ml
heparin (5000 IU/ml; CP Pharmaceuticals Ltd, Wrexham,
UK) was injected via a tail vein to reduce blood clotting fol-
lowed by removal of 2 ml blood by cardiac puncture into
heparinized tubes. Animals were exsanguinated with 200 ml
ice-cold heparinized 0·9 % (w/v) saline and organs were dis-
sected out immediately. Plasma samples were separated by
centrifugation at 600 g for 30 min. The haemoglobin concen-
trations of the cardiac blood sample and exsanguinated fluid
were measured using a haemoglobin assay kit (Sigma,
Poole, Dorset, UK) to allow calculation of blood volume as
described previously (Abd El-Mohsen et al. 2004). The
removed tissues, liver, kidneys, spleen, heart, small intestine,
large intestine, lung and brain, were weighed and then hom-
ogenized in ice-cold 0·9 % (w/v) saline (10 vol./g tissue)
using an Ultra Turrax homogenizer (Janke & Kunkel, Staufen,
Germany) for 40 s. Urine and faeces from rats housed in meta-
bolic cages were collected for the 18 h experiments. Intestinal
contents were obtained by finger pressure and flushing with
0·9 % (w/v) saline alone. Samples were divided for either
direct measurement of radioactivity by scintillation counting
or frozen for subsequent extraction for HPLC analysis.
Measurement of radioactivity
Plasma (100ml) or tissue homogenate (400ml) was mixed
with 4 ml Ultima Gold scintillation cocktail (Packard Bios-
ciences, Beaconsfield, UK) designed to withstand quenching
and to solubilize protein. Radioactivity was measured using
a Packard Liquid Scintillation Counter (Tri-carb 2900TR)
where counts were taken over a 5 min period and corrected
for background. Data for organ weight and dpm of digested
sample allowed calculation of organ content radioactivity. Per-
centage retention by each organ was then calculated. Percen-
tage excretion was similarly determined in urine and faeces
collected for 18 h following resveratrol administration.
Autoradiography was performed as previously described
(Abd El-Mohsen et al. 2004) on tissue sections obtained
from rats 2 h after gastric gavage of [3H]resveratrol.
Extraction of samples for HPLC analysis
Plasma (500ml) was de-proteinized with 100ml 20 % (w/v)
TCA and then extracted with 500ml ice-cold methanol. The
extract obtained following centrifugation was evaporated to
dryness under N and the residue dissolved in 500ml 20 %
(v/v) methanol in 1 % (w/v) acetic acid for quantitative
HPLC analysis. Extraction of resveratrol and its metabolites
from rat tissues was performed by mixing the homogenates
with an equal volume of ice-cold methanol followed by vigor-
ous vortexing for 1 min. The methanol extract obtained after
centrifugation was dried under vacuum at 308C by rotary
evaporation and then the extracts were treated as described
earlier. Urine samples were injected directly or after treatment
with b-glucuronidase enzyme. This was done by mixing urine
samples with an equal volume of sodium acetate buffer (pH
3·8) containing 12 000 U enzyme/ml and then incubated for
2 h at 378C before analysis.
Quantitative determination of resveratrol and its metabolites
was based on external standards. Calibration curves were con-
ducted over the range 0·3–30mM for plasma and tissue
samples and were linear over the entire range with correlation
coefficient values 30·995. Recovery experiments were per-
formed to investigate the stability of both the unlabelled and
the [3H]resveratrol under the conditions described.
HPLC analysis was performed on a Hewlett Packard Agilent
1100 system with a photodiode array detector (Model 1315A;
Hewlett Packard) and Beta-RAM flow-through monitor
(Model 3B; LabLogic Systems Ltd, Sheffield, UK). The samples
were injected on to a Nova-pak C18 column (4·6 £ 250 mm)
fitted with a guard column (4·6 £ 15 mm, 4 mm). Column tem-
perature was set at 308C. Injection volume was 100ml for all
samples. The mobile phase A consisted of methanol–water–5
M-HCl (5:94.9:0.1, by vol.) and mobile phase B of aceto-
nitrile–water–5 M-HCl (50:49.9:0.1, by vol.). The gradient
applied was as follows: from 0 to 5 min 100 % A; from 5 to
40 min to 50 % B; from 40 to 60 min to 100 % B; from 60 min
to 65 min to 0 % B. Run time was 65 min followed by a 10 min
delay prior to the next injection. Following UV detection, the
eluate passed into the radiochromatography detector after
mixing with the liquid scintillation cocktail (FlowLogic Max-
Count; Lablogic Systems) in the ratio 1:3.
Resveratrol was initially identified using comparative reten-
tion times of pure standard and photodiode array spectra. The
presence of glucuronide conjugates was confirmed (prior to
liquid chromatography–MS/MS as described later) by incu-
bating urine samples after b-glucuronidase treatment (as
described earlier) and examining the decrease in the suspected
Fate of resveratrol after oral administration 63
glucuronide peak and concomitant increase in the respective
aglycone peak.
Liquid chromatography–MS analysis was performed using
a Finnigan LCQ Deca XP quadrupole ion trap mass spec-
trometer. Separation was performed using a Phenomenex
C18 column (2 mm £ 5 mm) with the following gradient
(phase A: 0·05 % (w/v) formic acid in water; phase B:
0·05 % (w/v) formic acid in acetonitrile). The liquid chroma-
tography–MS gradient was 0–5 min 100 % A, 5–40 min
from 100 % A to 50 % A, 40–60 min to 0 % A, 60–65 min
0 % A. Compounds were detected using a full ion scan and
identified by performing product ion scans on selected ions.
Calculations and statistics
Values are given as means with their standard errors. Statisti-
cal analysis was performed using an unpaired t test (Instat)
and considered significant at P,0·05.
Results
Absorption and tissue distribution of radioactivity
In order to calculate the concentrations of [3H]resveratrol-
derived radioactivity detected in different tissues and body
fluids, the total counts of the administered dose was defined
as 100 % (based on dpm) and the measured tissue levels
were expressed as respective percentages of this total.
Table 1 illustrates that at 2 h post-gavage, most of the recov-
ered radioactivity, approximately 76·2 %, was still present in
the gastrointestinal tract. At the same time-point, concen-
trations in plasma had reached only 1·7 % of the total dose
administered, while the highest concentrations detected in tis-
sues were found in liver and kidney and reached 0·98 % and
0·59 %, respectively. Only trace amounts of radioactivity
(,0·1 % of administered dose) were detected in the brain,
lungs, heart and spleen, with the aggregate value for all the tis-
sues investigated being ,2 %.
Repeating the dosing paradigm described earlier, with the
exception that all plasma and tissue samples were collected
at 18 h post-[3H]resveratrol administration, the following
results were obtained. The concentrations of [3H]resveratrol-
derived radioactivity detected in plasma represented only
0·48 % of the total dose administered, whereas the sum of
all measured tissue doses reached only 0·35 % of the total
dose ingested (Table 1). Adding the radioactivity concen-
trations of plasma and organs as well as the concentrations
measured in the content of the gastrointestinal tract (approxi-
mately 5·1 % total dose), the urine (approximately 3·3 % total
dose) and the excreted faeces (approximately 1·6 % total
dose), approximately 11 % total dose administered was
accounted for at 18 h post-administration.
If absorption is measured as the difference between the total
counts gavaged and the total amount recovered in the stool
(18 h faeces plus gastrointestinal tract content), it appears
that almost 90 % of the administered resveratrol was absorbed
inside the body over the 18 h period. Surprisingly, the concen-
trations detected in urine, which would represent a part of the
absorbed (and subsequently excreted) resveratrol, were only
3·3 %. The undetected radioactivity is likely to reflect loss
via perspiration or respiratory water and/or the accumulation
of a high proportion of the administered resveratrol in other
tissues, such as skeletal muscle and adipose tissue. Such tis-
sues were not examined in the present study, as we were pri-
marily interested in the tissue concentrations and disposition
of metabolites in organs relevant to the major degenerative
diseases (i.e. heart, liver and brain).
Although the liver and kidneys had the highest concen-
trations at 2 h (Fig. 1), the amount detected at 18 h reached
only around 10 and 25 %, respectively, of what was detected
at 2 h. In contrast, although the brain initially contained
trace amounts of the administered dose, 43 % of the concen-
trations detected at 2 h were also recovered at 18 h.
Autoradiography demonstrated the presence of 3H-activity
within the blood vessels of all organs investigated, but not
within most organ-specific cells (Fig. 2). In addition, silver
grains representing the presence of 3H were demonstrated
within the tubular fluid in the kidney and intervillus space in
the small intestine.
Identification of resveratrol metabolites in rat tissue extracts
The chemical nature of the [3H]trans-resveratrol-derived
radioactivity detected in rat plasma and various tissues
was investigated using HPLC analysis with photodiode
array and radioactive detection (Fig. 3, left and right
panels, respectively). The analysis of a mixture of authentic,
unlabelled resveratrol and native [3H]trans-resveratrol
demonstrated that the test compound elutes at a retention
time of 43·5 min, and that this peak has the characteristic
UV spectrum of resveratrol (peak 2; Fig. 3(a)). Plasma
extracts obtained from animals 2 h after dosing with
[3H]trans-resveratrol revealed a peak with the same spectral
and chromatographic characteristics as the authentic standard
(peak 2), and was thus assigned to be aglyconic resveratrol.
In addition, a major peak possessing a resveratrol-like UV
spectrum, but a retention time of 36·2 min (peak 1;
Fig. 3(c)), could be identified. With a retention time that
is 7 min shorter as compared with native resveratrol, peak
1 is more hydrophilic than the native test compound, thus
it was hypothesized to represent a resveratrol O-glucuronide.
HPLC profiles for control samples obtained from animals
that did not ingest resveratrol did not exhibit either peak
1 or peak 2 (Fig. 3(b)).
Table 1. Concentrations of [3H]trans-resveratrol-derived radioactivity
detected 2 and 18 h post-gavage†
Mean values with their standard errors (six rats per group)
2 h 18 h
Mean SEM Mean SEM
Tissues 1·7 0·44 0·35* 0·11
Plasma 1·7 0·25 0·48** 0·05
Gastrointestinal tract 76·2 8·8 5·1** 1·04
Urine – 3·3 0·01
Faeces – 1·55 0·28
Total radioactivity recovered 79·6 9·5 10·7** 1·5
Mean values were significantly different between 2 and 18 h (unpaired t test):
*P,0·05; **P,0·001.
† The total counts of the administered dose was defined as 100 % (based on dpm)
and the measured tissue concentrations were expressed as respective percen-
tages of this total.
For details of procedures, see p. 63.
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Fig. 1. Concentrations of [3H]trans-resveratrol in rat tissues at 2 h (A) and 18 h (B) after gastric gavage. The total count of the administered dose was defined as
100 % (based on dpm) and the measured tissue levels were expressed as respective percentages of this total. For details of procedures, see p. 63. Values are
means with their standard errors depicted by vertical bars (six animals per group). Mean values were significantly different between 2 and 18 h: *P,0·05;
**P,0·001.
Fig. 2. Autoradiographs of tissue sections obtained from rats 2 h after gastric gavage of [3H]trans-resveratrol. Tissues have been counterstained with haemotoxylin
and eosin. Silver grains representing the presence of 3H-activity within blood vessels in all tissues plus tubular fluid in the kidney and intervillus space in the small
intestine are shown (! ). Scale bars ¼ 50mm. For details of procedures, see p. 63.
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Analyses of urine samples (Fig. 3(d)) also identified two
major radioactive peaks, one of which was identical to aglyco-
nic resveratrol (peak 2). However, peak 1 appeared to consist
of two radiolabelled compounds co-eluting at the same reten-
tion time. Thus it may be assumed that peak 1 represents two
compounds with closely related structures. Treatments of
urine with b-glucuronidase resulted in the disappearance of
peak 1, and a corresponding increase was observed in the
resveratrol aglycone peak (peak 2; Fig. 3(e)), which strongly
supports the hypothesis that peak 1 represented two resvera-
trol-O-glucuronides, potentially derivatized on either position
3 or 5 of the trans-resveratrol molecule. Importantly, no
other signals on the UV trace or on the radioactive chromato-
gram were observed, indicating that no other major
[3H]resveratrol-derived metabolites were present.
Liquid chromatography–MS analysis confirmed the identity
of resveratrol (peak 2) and its O-glucuronides (Fig. 4). Resver-
atrol is identified by comparison with the retention time of the
authentic standard and the fragmentation reaction m/z
229 ! m/z 135. A signal, assigned to the glucuronide, with
the predicted molecular weight (404 Da) and an expected frag-
ment (neutral loss of glucuronic acid, 176 Da) could be
detected in urine, plasma and small intestine cell extracts.
None of these signals was found in the control samples.
Concentrations of resveratrol metabolites at 2 and 18 h
were calculated in plasma and tissues based on UV-absorption
peaks as assessed using a photodiode array detector, and calcu-
lated using the area under the curve for each peak, respectively.
All analyses were based on calibration curves established using
different concentrations of authentic, unlabelled trans-resvera-
trol. Fig. 5 shows resveratrol/metabolite concentrations
expressed as nmol/ml plasma or g tissue. In a similar manner
to the radioactive detection, the total concentration of resvera-
trol aglycone and its glucuronide declined at 18 h compared
with 2 h. It was clear that total measurement of radioactivity
using scintillation counting was a more sensitive tool since
the concentrations of metabolites at 18 h was below the detec-
tion limit in some tissue samples following injection on to the
HPLC system. In all tissue and plasma samples obtained at 2 h
post-gavage, resveratrol glucuronide was the only major
metabolite. Plasma concentrations of resveratrol glucuronide
reached 7mM at 2 h but disappeared completely at 18 h. A simi-
lar picture was observed in the kidney; however, in the liver,
heart, lungs and the brain, the detected metabolite at 18 h was
mainly the aglycone.
Discussion
In the present study, we have studied the distribution of trans-
resveratrol, a dietary stilbene, in rat tissues following oral
administration. In particular, we have assessed the fate of
3H-labelled resveratrol and investigated the chemical nature
of its metabolites.
The amounts of radioactivity found in plasma and tissues
2 h after resveratrol gavage were relatively low, with almost
all the radioactivity in the intestinal tract. These observations
are consistent with previous studies, during which resveratrol
was orally administered to rats (Soleas et al. 2001; Vitrac et al.
2003). The disappearance of radioactivity from the gastroin-
testinal tract after 18 h, and the very low levels measurable
in the faeces, support the previous suggestion that the faecal
route is a minor way of elimination (Vitrac et al. 2003). Fail-
ure to account for the total administered radioactivity might be
caused by retention of resveratrol in tissues such as skeletal
muscle, skin, bone and adipose tissues. This is acceptable
based on the fact that these tissues account for 80 % of the
animal weight.
Resveratrol-O-glucuronides have been previously identified
in rat plasma after the oral administration of the aglycone
(Marier et al. 2002; Yu et al. 2002). In agreement, our ana-
lyses showed that the major metabolite in the plasma was
the glucuronide conjugates reaching concentrations of 7mM.
This is comparable to studies in man where plasma values
obtained were ranging between 2 and 4mM following the
intake of 25 mg pure resveratrol (Walle et al. 2004) or
600 ml red wine (Vitaglione et al. 2005). The absence of
O-sulphated resveratrol conjugates in the present experiments
is in agreement with a recent study describing the effect of the
administered dose on the nature of resveratrol metabolites
(Wenzel et al. 2005). Wenzel et al. (2005) propose that O-sul-
phation via O-sulphotransferases is a secondary elimination
pathway only supporting O-glucuronidation when a high
dose of resveratrol is administered to animals.
In accordance with the present results, micro-autoradio-
graphic evidence of the distribution of resveratrol-derived
radioactivity in the rat liver and kidney was previously demon-
strated (Vitrac et al. 2003), but no data on the chemical nature
of this radioactivity were provided. The predominance of con-
jugated resveratrol in plasma at 2 h would suggest that these
derivatives are also more likely to reach the tissues. However,
contradictory reports exist on the possibility that resveratrol
glucuronide is the biologically active form of resveratrol.
Resveratrol was reported to be more potent in blocking the
function of the aryl hydrocarbon receptor (required for the
conversion of proximal carcinogens to metabolites) when
administered to rats than when incubated with cell cultures
in vitro, implying the biological activity of metabolites
(Casper et al. 1999; Soleas et al. 2001). On the other hand,
the glucuronides possessed no cytotoxic or antiviral activities
compared with the potent anti-HIV activity of the parent com-
pound resveratrol when tested in cell culture experiments
using human peripheral blood mononuclear cells (Wang et al.
2004).
The present results showed that 2 h following the adminis-
tration of resveratrol, while the liver and kidneys retained
only the glucuronide, in other tissues such as the lungs and
brain, detectable levels of the aglycone were found. Moreover,
more tissues, including the liver, retained a higher ratio of the
aglycone to the glucuronide at 18 h post-gavage compared
with their ratio at 2 h. Due to the absence of resveratrol
Fig. 3. HPLC detection of resveratrol and its metabolites using UV-detection at 290 nm (left panels) and 3H-detection (right panels). For details of procedures, see
p. 63. (a), Standard resveratrol; (b), control plasma extract; (c), plasma extract from rats 2 h after resveratrol gavage; (d), urine collected for 18 h after resveratrol
gavage; (e), post-enzymatic urine sample collected for 18 h after resveratrol gavage. AU, absorbance units; peak 1, resveratrol glucuronide; peak 2, resveratrol.
UV spectra (200–600 nm) are shown at the top.
R
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aglycone in the plasma, the present results support the possi-
bility that the ubiquitously existing b-glucuronidase could
convert the metabolites back to resveratrol locally or systemi-
cally. Alternatively, the preferential uptake of the aglycone
form into cells could lead to its localization in tissues, i.e.
heart, even though it was undetectable in plasma.
The radioactive concentrations detected in plasma and tis-
sues 18 h after [3H]resveratrol administration were consider-
ably lower than at the 2 h time-point, especially in the
kidneys where concentrations dropped to 10 % of that detected
at 2 h. This indicates that renal excretion might be the major
way of elimination of the 3H-label, an observation supported
by the high radioactive concentrations found in urine. In our
previous study with naringenin (Abd El-Mohsen et al.
2004), high excretion was observed in the urine, nevertheless,
radioactivity accumulating in tissues increased over time,
suggesting the existence of other slowly absorbed metabolites.
It is possible that resveratrol possess faster excretion and
hence less tissue retention. However, if indeed resveratrol
was subjected to further metabolism, it is logical to assume
that these metabolites carrying the 3H-label will be excreted
in urine. Interestingly, dihydroresveratrol was reported as a
urinary metabolite following the oral ingestion of resveratrol
in human subjects (Walle et al. 2004). Our urinary excretion
data showing the absence of this metabolite in rat urine indi-
cate differences in the metabolic pathway responsible for the
formation of such a metabolite in man.
Associations between the urinary excretion of simple phe-
nolics such as hydroxyhippuric acid and hydroxyphenylacetic
acid and high flavonoid intake have also been observed
through a number of human studies on the metabolism of diet-
ary polyphenols (Bravo et al. 1994; Gross et al. 1996; Rechner
et al. 2001, 2002). In our previous studies, 3-(4-hydroxyphe-
nyl) propionic acid and p-hydroxbenzoic acid were detected
in urine following gavage of naringenin and pelargonidin to
rats, respectively (Abd El-Mohsen et al. 2004, 2005). Contrary
to that, with resveratrol, urine samples did not show any radio-
active peaks, which could be attributed to phenolic degra-
dation products. The present results show that resveratrol
does not serve as a substrate for enzymes of colonic
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microflora, possibly due to the absence of the C ring and the
high stability of the trans-stilbene structure (Trela & Water-
house, 1996).
In summary, the present study provides well-characterized
data of the metabolic fate of resveratrol through the use of
HPLC with on-line radioactivity detection. The present data
indicate that there are no phenolic degradation products
formed following resveratrol consumption, suggesting that
resveratrol is not subject to degradation by large intestinal
bacteria. Furthermore, whilst the glucuronide is the predomi-
nate form in the plasma, resveratrol aglycone may represent
the main form present in the tissues. The present study pro-
vides additional information about the nature of resveratrol
metabolites and which forms might be responsible for its in
vivo biological effects.
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